JPWO2020146822A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020146822A5
JPWO2020146822A5 JP2021538484A JP2021538484A JPWO2020146822A5 JP WO2020146822 A5 JPWO2020146822 A5 JP WO2020146822A5 JP 2021538484 A JP2021538484 A JP 2021538484A JP 2021538484 A JP2021538484 A JP 2021538484A JP WO2020146822 A5 JPWO2020146822 A5 JP WO2020146822A5
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
hydrogen
benzothiazol
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021538484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517316A (ja
JP2022517316A5 (https=
JP7680955B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/013217 external-priority patent/WO2020146822A1/en
Publication of JP2022517316A publication Critical patent/JP2022517316A/ja
Publication of JP2022517316A5 publication Critical patent/JP2022517316A5/ja
Publication of JPWO2020146822A5 publication Critical patent/JPWO2020146822A5/ja
Priority to JP2024228232A priority Critical patent/JP2025060830A/ja
Application granted granted Critical
Publication of JP7680955B2 publication Critical patent/JP7680955B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021538484A 2019-01-11 2020-01-10 ロイコトリエン合成阻害剤 Active JP7680955B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024228232A JP2025060830A (ja) 2019-01-11 2024-12-25 ロイコトリエン合成阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962791641P 2019-01-11 2019-01-11
US62/791,641 2019-01-11
PCT/US2020/013217 WO2020146822A1 (en) 2019-01-11 2020-01-10 Leukotriene synthesis inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024228232A Division JP2025060830A (ja) 2019-01-11 2024-12-25 ロイコトリエン合成阻害剤

Publications (4)

Publication Number Publication Date
JP2022517316A JP2022517316A (ja) 2022-03-08
JP2022517316A5 JP2022517316A5 (https=) 2023-01-25
JPWO2020146822A5 true JPWO2020146822A5 (https=) 2023-01-25
JP7680955B2 JP7680955B2 (ja) 2025-05-21

Family

ID=71520894

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021538484A Active JP7680955B2 (ja) 2019-01-11 2020-01-10 ロイコトリエン合成阻害剤
JP2024228232A Pending JP2025060830A (ja) 2019-01-11 2024-12-25 ロイコトリエン合成阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024228232A Pending JP2025060830A (ja) 2019-01-11 2024-12-25 ロイコトリエン合成阻害剤

Country Status (11)

Country Link
US (2) US11976052B2 (https=)
EP (1) EP3908278A4 (https=)
JP (2) JP7680955B2 (https=)
KR (2) KR102920650B1 (https=)
CN (1) CN113784713A (https=)
AU (2) AU2020206036A1 (https=)
BR (1) BR112021013637A2 (https=)
CA (1) CA3126021A1 (https=)
MX (1) MX2021007967A (https=)
SG (1) SG11202107080VA (https=)
WO (1) WO2020146822A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3908278A4 (en) * 2019-01-11 2022-09-28 Naegis Pharmaceuticals Inc. INHIBITORS OF LEUKOTRIEN SYNTHESIS

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661499A (en) 1985-06-18 1987-04-28 Merck Frosst Canada, Inc. 2-[(substituted)-phenoxymethyl]quinolines
GB9122590D0 (en) * 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
WO1994006802A1 (fr) 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
ES2062943B1 (es) 1993-03-23 1995-11-16 Uriach & Cia Sa J Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
US5486612A (en) * 1993-12-14 1996-01-23 Eli Lilly And Company N-benzyl dihydroindole LTD4 antagonists
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US5783586A (en) 1996-10-01 1998-07-21 Abbott Laboratories Heteroarylmethoxyphenylthioalkyl carboxylates as inhibitors of leukotriene biosynthesis
EP0968179B1 (en) * 1997-02-25 2002-09-25 Syngenta Participations AG N-sulphonyl and n-sulphinyl amino acid amides as microbiocides
ATE233104T1 (de) * 1997-09-18 2003-03-15 Janssen Pharmaceutica Nv Kondensierte imidazolderivate zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
PL359619A1 (en) 2000-06-23 2004-08-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2004513935A (ja) 2000-11-17 2004-05-13 ノボ ノルディスク アクティーゼルスカブ グルカゴンアンタゴニスト/逆アゴニスト
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
US20050070506A1 (en) * 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
WO2004063147A1 (en) 2003-01-10 2004-07-29 Novo Nordisk A/S Salts and solvates of glucagon antagonists
US7329682B2 (en) 2003-04-03 2008-02-12 Ewha University-Industry Collaboration Foundation Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
CN1856490A (zh) * 2003-07-28 2006-11-01 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
UA86283C2 (uk) 2005-01-07 2009-04-10 Пфайзер Продактс Инк. Гетероароматичні сполуки хіноліну і їх застосування як інгібіторів pde10
US20060223792A1 (en) * 2005-03-31 2006-10-05 Butler Christopher R Phenyl and pyridyl LTA4H modulators
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
US7939528B2 (en) * 2005-10-13 2011-05-10 Glaxosmithkline Llc Heterocycle compounds
DE102006021878A1 (de) 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
AU2008256922B2 (en) 2007-05-23 2011-07-28 Novartis Ag Raf inhibitors for the treatment of thyroid cancer
AR069126A1 (es) * 2007-10-31 2009-12-30 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
SI2336125T1 (sl) * 2008-04-11 2013-04-30 Janssen Pharmaceutica N.V. Tiazolopiridin-2-iloksi-fenil in tiazolopirazin-2-iloksi-fenil amini kot modulatorji levkotrien a4 hidrolaze
WO2009132202A2 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
MX2010013683A (es) 2008-06-13 2011-04-26 Novartis Ag Bencimidazoles sustituidos para neurofibromatosis.
TW201010977A (en) 2008-08-12 2010-03-16 Takeda Pharmaceutical Amide compound
WO2010059163A1 (en) 2008-11-21 2010-05-27 Hassan Hamza Adjustable vacuum relief safety valve system for swimming pools and spas
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
WO2014077401A1 (ja) 2012-11-19 2014-05-22 武田薬品工業株式会社 含窒素複素環化合物
WO2014129796A1 (en) 2013-02-20 2014-08-28 Lg Life Sciences Ltd. Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
CN104045552B (zh) 2013-03-13 2019-06-11 江苏先声药业有限公司 作为神经保护剂的药用化合物
US20160101106A1 (en) 2013-05-07 2016-04-14 Inhibikase Therapeutics, Inc. Methods for treating hcv infection
SG11201509351UA (en) 2013-06-10 2015-12-30 Bayer Pharma AG Novel compounds for the treatment of cancer
EP3102569A1 (en) 2014-02-06 2016-12-14 AbbVie Inc. 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
SG11201609050UA (en) * 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
EP3328860B2 (en) 2015-07-28 2022-11-02 UDC Ireland Limited Process for the preparation of benzimidazo[1,2-a]benzimidazoles
BR112018003711A2 (pt) * 2015-08-26 2018-09-25 Texas A & M Univ Sys método para sensibilização de um parasita a um fármaco e método para prevenir infecção sintomática de um paciente por um parasita ou tratar infecção de um paciente por um parasita com um fármaco
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CN107383014B (zh) 2017-06-21 2019-04-30 南方医科大学 一种1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法和应用
EP3908278A4 (en) * 2019-01-11 2022-09-28 Naegis Pharmaceuticals Inc. INHIBITORS OF LEUKOTRIEN SYNTHESIS

Similar Documents

Publication Publication Date Title
JP2024050527A5 (https=)
RU2378259C2 (ru) Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции
JP6424219B2 (ja) 複素芳香環−ベンジル−アミド−サイクルコアを含むオートタキシン阻害剤
JP2002527438A (ja) 4,5−ジヒドロ−イソオキサゾール誘導体及びそれらの製薬学的使用
EA016203B1 (ru) Производные амина
JPH09505829A (ja) 炎症および炎症関連障害を処置するための1,4,5−トリフェニルピラゾリル化合物
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
JP2007519692A5 (https=)
JP2010513434A5 (https=)
JP2007502265A5 (https=)
JP2013542267A5 (https=)
JP2020506192A5 (https=)
JP2021510692A5 (https=)
JP2003505383A5 (https=)
JP2018515489A5 (https=)
KR20090016504A (ko) 선택적 칸나비노이드 cb1 수용체 길항제로서의 황 함유 피라졸 유도체
JP2025060830A5 (https=)
JP2004525183A5 (https=)
US11299485B2 (en) Thiophene derivative and use thereof
JPWO2020146822A5 (https=)
RU2007127864A (ru) Производные n-[(4, 5-дифенил-3-алкил-2-тиенил)метил]амина (амид, сульфонамид, карбамат и карбамид) в качестве антагонистов рецепторов св1 каннабиноидов
JPH10509165A (ja) 5−ht▲下1▼受容体アゴニストとして有用なピペラジン、ピペリジン及びテトラヒドロピリジン誘導体
CN1181079A (zh) 作为阿朴脂蛋白-b合成抑制剂的新型三唑酮
JPWO2021020362A5 (https=)
JPWO2021151865A5 (https=)